These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26382174)

  • 1. Influence of Amyloid-β on Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study.
    Liu W; Wong A; Au L; Yang J; Wang Z; Leung EY; Chen S; Ho CL; Mok VC
    Stroke; 2015 Nov; 46(11):3074-80. PubMed ID: 26382174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
    Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
    JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Montreal cognitive assessment versus mini-mental state examination against hypertension and hypertensive arteriopathy after transient ischemic attack or minor stroke.
    Webb AJ; Pendlebury ST; Li L; Simoni M; Lovett N; Mehta Z; Rothwell PM
    Stroke; 2014 Nov; 45(11):3337-42. PubMed ID: 25248911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors and Cognitive Relevance of Cortical Cerebral Microinfarcts in Patients With Ischemic Stroke or Transient Ischemic Attack.
    Wang Z; van Veluw SJ; Wong A; Liu W; Shi L; Yang J; Xiong Y; Lau A; Biessels GJ; Mok VC
    Stroke; 2016 Oct; 47(10):2450-5. PubMed ID: 27539302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Zhang N; Zhang L; Li Y; Gordon ML; Cai L; Wang Y; Xing M; Cheng Y
    J Alzheimers Dis; 2017; 60(1):87-95. PubMed ID: 28777752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.
    Ellis KA; Lim YY; Harrington K; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P;
    J Alzheimers Dis; 2013; 34(4):861-71. PubMed ID: 23302660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
    Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
    J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease?
    Lim YY; Ellis KA; Harrington K; Pietrzak RH; Gale J; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P
    J Alzheimers Dis; 2013; 33(4):1167-76. PubMed ID: 23160011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.
    Storandt M; Mintun MA; Head D; Morris JC
    Arch Neurol; 2009 Dec; 66(12):1476-81. PubMed ID: 20008651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.